コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of Ldha, Mct1, and Mct4 as well as with more proliferative disease.
2 ting future therapeutic targets for vascular proliferative disease.
3 oma viral nephropathy, and no posttransplant proliferative disease.
4 issue injury and the progression of vascular-proliferative disease.
5 s relevant to the onset and progression of a proliferative disease.
6 therapeutic significance in the treatment of proliferative disease.
7 the molecular mechanisms underlying vascular proliferative disease.
8 itute an effective intervention for arterial proliferative disease.
9 es of neovascularization and corneal surface proliferative disease.
10 MCs may be beneficial in preventing vascular proliferative diseases.
11 repair, as well as pathogenesis of vascular proliferative diseases.
12 le cells (SMCs) plays a key role in vascular proliferative diseases.
13 and a therapeutic target in the treatment of proliferative diseases.
14 P) and that human PNP is a target for T-cell proliferative diseases.
15 nt wound healing process or to treat various proliferative diseases.
16 ular events important in the pathogenesis of proliferative diseases.
17 t may contribute to the pathogenesis of some proliferative diseases.
18 in the treatment of ocular inflammatory and proliferative diseases.
19 elopment of reagents for treating immune and proliferative diseases.
20 cycle is considered a key event in vascular proliferative diseases.
21 presenting a therapeutic target for vascular proliferative diseases.
22 e in the pathogenesis of leukemias and other proliferative diseases.
23 hat may regulate the progression of vascular proliferative diseases.
24 peutic target for the prevention of vascular proliferative diseases.
25 tic effects of retinoids in inflammatory and proliferative diseases.
26 activity, particularly in patients with less proliferative diseases.
27 ations for the treatment of inflammatory and proliferative diseases.
28 constitute a possible treatment for vascular proliferative diseases.
31 rstanding of the pathophysiology of vascular proliferative diseases and for the development of molecu
32 rus (EBV) is often present in EBV-associated proliferative diseases and is critical for the immortali
33 ld-type Flt3 characterize many hematopoietic proliferative diseases and neoplasms, providing a potent
36 play a major role in the etiology of benign proliferative disease in the context of an aging tissue
39 prevention and treatment of asbestos-induced proliferative diseases including lung cancers, mesotheli
40 ne proteins associated with degenerative and proliferative disease, including lung fibrosis (surfacta
41 re implicated in the pathogenesis of several proliferative diseases, including atherosclerosis and ca
42 c strategy to reduce progression of vascular proliferative diseases, including atherosclerosis and re
43 inflammatory responses that lead to vascular proliferative diseases, including atherosclerosis and re
46 mportant role in the development of vascular proliferative diseases, including restenosis and atheros
47 cell lymphoma (CTCL) constitutes a malignant proliferative disease involving mostly CD4(+) T cells ar
50 growth in BaF3 cells, and induces a myeloid proliferative disease (MPD) with features of megakaryobl
51 anular lymphocyte (LGL) leukemia is a clonal proliferative disease of T and natural killer (NK) cells
53 Pulmonary arterial hypertension (PAH) is a proliferative disease of the pulmonary vasculature that
55 t has been implicated in the pathogenesis of proliferative diseases of lymphocytes and tumors of epit
57 ic fungal infections in patients treated for proliferative diseases of the hematopoietic system are c
58 s been implicated in regenerative growth and proliferative diseases of the human bladder epithelium (
59 n humans for the treatment of this and other proliferative diseases of the retina involving fibrosis
60 ecurrence of primary disease, sepsis, lympho-proliferative disease, or vascular or biliary complicati
61 aglobulinemia in a subset of X-linked lympho-proliferative disease patients without involvement of Ep
62 tinuing search for medicinal agents to treat proliferative diseases, quinazoline derivatives were syn
63 uman herpesvirus 8, is associated with three proliferative diseases ranging from viral cytokine-induc
64 n ACCORD-Eye as >/= 3 steps (ETDRS scale) or proliferative disease requiring laser or vitrectomy trea
65 that bacterial components can contribute to proliferative disease states in squamous epithelium thro
68 eral signal transduction pathways related to proliferative diseases such as cancer, atherosclerosis,
71 ytostatic gene therapy in models of vascular proliferative disease using antisense oligodeoxynucleoti
72 ing our search for medicinal agents to treat proliferative diseases, we have discovered 2-substituted
73 therapeutic intervention against a number of proliferative diseases, we have discovered the 2-aminopy
74 e than half of patients with X-linked lympho-proliferative disease, which is caused by a defect in th
76 treatment or prevention of immunological and proliferative diseases without gastrointestinal or hemat
77 eutic equivalent for ASA in inflammatory and proliferative diseases without the deleterious effects o
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。